<rt id="ossuk"></rt>
產品描述：
DC101-CP132單克隆抗體是原始DC101單克隆的重組嵌合型抗體。可變結構域序列與原始DC101相同，但是恒定區序列已經從大鼠IgG1變為小鼠IgG2a。DC101-CP132單克隆抗體像原始大鼠IgG1抗體一樣，不包含Fc突變。
DC101-CP132單克隆抗體能與小鼠VEGFR-2(血管內皮生長因子受體2)反應，VEGFR-2也稱為CD309、KDR和Flk-1。VEGFR-2是酪氨酸蛋白激酶家族的成員。當結合到其配體血管內皮生長因子時發揮生理作用，血管內皮生長因子受體-2在血管發育和通透性中起關鍵作用。血管內皮生長因子受體-2在成人心臟、肺、腎、腦和骨骼肌的內皮細胞中高表達，在其他組織中低表達。DC101單克隆抗體已被證明在體內抑制VEGFR-2信號傳導。
產品詳情：
產品名稱 | RecombiMAb anti-mouse VEGFR-2 |
產品貨號 | CP132 |
產品規格 | 1/5/25/50/100mg |
反應種屬 | Mouse |
克隆號 | DC101-CP132 |
同種型 | Mouse IgG2a(switched from rat IgG1) |
免疫原 | Mouse VEGFR-2-SEAPs soluble receptor |
實驗應用 | in vivo blocking of VEGF/VEGFR-2 signaling* |
產品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 µm filtration |
純化方式 | Protein G |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C，不能冷凍保存。 |
推薦同型對照 | InVivoPlus mouse IgG2a isotype control, unknown specificity（貨號BP0085） |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer（貨號IP0070） |
該產品自上市已被多篇SCI文獻引用，品質有保證，以下是部分已發表的文獻引用：
應用 | 文章 |
體內VEGF/VEGFR-2信號阻斷 (in vivo blocking of VEGF/VEGFR-2 signaling) | 1. Ding, X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343. 2. Lee, H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature' Int J Radiat Oncol Biol Phys 91(3): 621-630. 3. Arulanandam, R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell 28(2): 210-224. 4. Kizhatil, K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process' PLoS Biol 12(7): e1001912. |
體內VEGF/VEGFR-2信號阻斷，體外VEGFR信號阻斷 (in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling) | 1.Larrayoz, M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4): 539-550. |
更多產品詳情請聯系 BioXCell 中國授權代理——欣博盛生物
在線咨詢
電話咨詢
